Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial Design
Glomerular Diseases · 07.04.2026 · 6 (1) · 103-112
DOI: 10.1159/000550524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Glomerular Diseases, online erschienen am 07.04.2026. Verfasst von John Devin Peipert und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Patient Reported Outcomes Research, Department of Applied Health Sciences, University of Birmingham, Birmingham, UK. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Nephrotic syndrome (NS) clinical trials often rely on biomarkers or clinical measures as primary endpoints, but these may not fully capture the treatment benefits that matter most to patients. Edema-related swelling, a central manifestation of NS, profoundly affects patients’ health-related quality of life, including physical function, severe physical and mental symptoms, and ability to participate in routine activities, highlighting the need for clinical outcome assessments (COAs) that directly measure its severity and impact. The PREPARing a clinical outcomes assessment set for Nephrotic Syndrome (Prepare-NS) project, supported by the United States Food and Drug Administration’s Center for Drug Evaluation and Research Pilot Grant Program, aims to address this unmet need.
Methods
We conducted qualitative interviews with and surveyed clinical trialists from industry, academia, and patient advocacy organizations. Each queried participants on how COAs, including patient- and observer-reported outcomes, could be used to demonstrate treatment benefit in trials. Participants were asked about preferences for timing, frequency, and format of COA assessment, as well as how COA-based endpoints could best capture swelling impacts, and how these might relate to other trial endpoints.
Results
Participants expressed strong support for COA-based endpoints to complement clinical or biomarker endpoints, noting that the impact of disease as represented by proteinuria does not fully capture potential treatment benefit to patients. We identified multiple endpoints to operationalize swelling COAs in clinical trials. Additional key considerations included optimal timing of assessments, feasibility of daily diaries (i.e., daily symptom ratings), potential confounding factors, and alignment of COAs with proteinuria or other endpoints.
Conclusions
Collectively, these insights inform the Prepare-NS initiative’s ongoing development and validation efforts. Incorporating standardized COAs in NS clinical trials could expand efficacy endpoints and pave the way for patient-centered NS drug development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Patient Reported Outcomes Research, Department of Applied Health Sciences, University of Birmingham, Birmingham, UK.
- Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK.
- Department of Medical Social Sciences, Feinberg School of Medicine, Chicago, IL, USA.
- Department of Physical Medicine and Rehabilitation and The Center for Health, Policy and Innovation (IHPI), University of Michigan Medical School, Ann Arbor, MI, USA.
- Division of Nephrology, Department of Pediatrics, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
- School of Public Health, Survey Research Center, University of Michigan, Ann Arbor, MI, USA.
Zitieren
APA
Peipert, J. D., Kuharic, M., Carlozzi, N. E., Hurt, C. N., Rahimi, A. E., Lai, J. S., Raghunathan, T., Hashemi, S., Trachtman, H., Oni, L., Scherr, R., Zhai, Y., & Salmon, E. (2026). Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial Design. Glomerular Diseases, 6(1), 103-112. https://doi.org/10.1159/000550524
Vancouver
Peipert JD, Kuharic M, Carlozzi NE, Hurt CN, Rahimi AE, Lai JS, et al. Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial Design. Glomerular Diseases. 2026;6(1):103-112. doi:10.1159/000550524
BibTeX
@article{Peipert2026,
author = {Peipert, John Devin and Kuharic, Maja and Carlozzi, Noelle E and Hurt, Courtney N and Rahimi, Ashley E and Lai, Jin-Shei and Raghunathan, Trivellore and Hashemi, Somayeh and Trachtman, Howard and Oni, Louise and Scherr, Rebecca and Zhai, Yan and Salmon, Eloise},
title = {Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial Design},
journal = {Glomerular Diseases},
year = {2026},
volume = {6},
number = {1},
pages = {103--112},
doi = {10.1159/000550524}
}
EUVIMED